JAMA Neurology 发表的两项阿尔茨海默病生物标志物研究显示,向受试者告知 APOE4 与 p-tau217 结果时,数字沟通相较临床医生远程医疗达到非劣效,且更具可扩展性。另一项研究指出,过去 18 个月美国 p-tau217 检测量增长超过 7 倍。
2 new studies on Alzheimer's biomarkers @JAMANeuro
—A randomized trial of digital communication vs clinician telehealth for results of APOE4 and p-tau217 support use of the former with non-inferiority and scalability
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856813?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaneurol.2026.4279
—In the past 18 months, p-tau217 testing went up over 7-fold in the United States https://jamanetwork.com/journals/jama/fullarticle/2856893?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2026.23534
来源:Eric Topol · x.com